Plain-English translation of NCT07903493 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing an experimental medication called , which is a type of antibody designed to help treat ankylosing spondylitis (a condition that causes inflammation in the spine). The study will give healthy volunteers a single injection of the medication at different dose levels to see how safe it is and how the body responds to it.
Before this medication can be tested in people with ankylosing spondylitis, researchers need to confirm it's safe and understand how the body processes it. This trial is the first step to gather that essential safety information.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection of the medication (or a placebo) under the skin. Researchers would then monitor you closely to check for any side effects and measure how your body responds to the treatment through blood tests and physical exams. The study involves healthy volunteers only, so you do not need to have ankylosing spondylitis to participate.
AI-generated summary from trial data · Nov 4, 2026 · Not medical advice
Australia
Safety & dosing
Sponsor
Mabsoft Therapeutics (Shanghai) Co., Ltd.
Collaborators
Mabsoft Therapeutics (Australia) Pty. Ltd., Mabsoft Therapeutics (Guangdong Hengqin) Co., Ltd.
Enrollment target
~32 participants
Started
November 2026
Primary completion
July 2027
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in November 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Changlong Liu
Mabsoft Therapeutics (Shanghai) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.